Search

Displaying results 6691 - 6700 of 10000 in total
  1. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    However, being on the controlled drug and substance act does not necessitate that the drug is approved for sale on the market. … Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug.

  2. Drug

    Nifurizone

    go.drugbank.com/drugs/DB19694
    Experimental

    The usage of the INN stem '-zone' in the name indicates that Nifurizone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurizone is a 5-nitrofuran derivative. Nifurizone has a monoisotopic molecular weight of 307.09 Da.

  3. Drug

    Nifurethazone

    go.drugbank.com/drugs/DB20112
    Experimental

    The usage of the INN stem '-azone' in the name indicates that Nifurethazone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurethazone is a 5-nitrofuran derivative. Nifurethazone has a monoisotopic molecular weight of 269.11 Da.

  4. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.[A39048]

  5. Drug

    Tampramine

    go.drugbank.com/drugs/DB19911
    Experimental

    The usage of the INN stem '-pramine' in the name indicates that Tampramine is a substance of the imipramine group. Tampramine has a monoisotopic molecular weight of 356.2 Da.

  6. Drug

    Citatuzumab Bogatox

    go.drugbank.com/drugs/DB06072
    Investigational

    VB6-845 is a humanized antibody fragment targeting EpCAM fused with the deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer.

  7. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  8. Drug

    BACTEK-R

    go.drugbank.com/drugs/DB16526
    Investigational

    Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.

  9. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  10. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.